For example, the MARIPOSA clinical trial of the first-line EGFR-MET antibody amivantamab plus the third-generation EGFR TKI lazertinib in EGFRm NSCLC reported an improved median PFS of 23.7 months compared to that of osimertinib, with OS data favoring amivantamab plus lazertinib as well [47,48]. Here, EGFR is linked to non-small cell lung carcinoma.